Otogenetics

Patients

  • GxVISION® Carrier Screening

  • EnVISION Non Invasive Prenatal® Screening

  • GxVISION® Hereditary Cancer Risk Assessment

Physicians

  • GxVISION® Carrier Screening

  • EnVISION Non-Invasive Prenatal® Screening

  • GxVISION® Hereditary Cancer Risk Assessment

  • GxVISION® Congenital Hearing Loss

Education Center

  • Physician Education Resources

  • Patient Education Resources

  • Patient Stories

Research & Partnerships

  • Research and Research Partners

  • GBinsight

Company

  • About Us

  • Contact Us

De novo mutation in ATP6V1B2 impairs lysosome acidification and causes dominant deafness-onychodystrophy syndrome

August 6, 2024

Yuan Y, Zhang J, Chang Q, Zeng J, Xin F, Wang J, Zhu Q, Wu J, Lu J, Guo W, Yan X, Jiang H, Zhou B, Li Q, Gao X, Yuan H, Yang S, Han D, Mao Z, Chen P, Lin X, Dai P. (2014) De novo mutation in ATP6V1B2 impairs lysosome acidification and causes dominant deafness-onychodystrophy syndrome. Cell Res. 24(11):1370-3. doi: 10.1038/cr.2014.77.

Otogenetics
  • 4553 Winters Chapel Rd., Suite 100 Atlanta, GA 30360
  • +1 (855)-686-4363
Contact Us

Patients

  • GxVISION® Carrier Screening

  • EnVISION Non Invasive Prenatal® Screening

  • GxVISION® Hereditary Cancer Risk Assessment

Physicians

  • GxVISION® Carrier Screening

  • EnVISION Non-Invasive Prenatal® Screening

  • GxVISION® Hereditary Cancer Risk Assessment

  • GxVISION® Congenital Hearing Loss

Education Center

  • Physician Education Resources

  • Patient Education Resources

  • Patient Stories

Research & Partnerships

  • Research and Research Partners

  • GBinsight

Company

  • About Us

  • Contact Us

  • Privacy Policy

© Otogenetics 2025 All Rights Reserved.